Eli Lilly-backed Oyster Therapeutics raises $60 million to push an oral tau degrader program

Oyster Therapeutics, a company backed by Eli Lilly, said it has raised $60 million to support its pipeline work focused on neurological degraders. The company’s lead program centers on an oral drug candidate designed to reduce tau, a protein that accumulates abnormally in conditions such as Alzheimer’s disease and other tauopathies.

According to the announcement reported in business coverage, the new financing will be used to advance the company’s lead program that targets tau through a degrader mechanism. A degrader is a drug modality intended not just to block a disease target, but to promote the target’s removal from cells, potentially changing how the underlying biology is addressed.

The reported emphasis on an oral route is notable because oral dosing is often pursued to improve convenience and adherence compared with therapies that require injection or infusion. For neurodegenerative disease programs, which may involve long-term treatment, route of administration can be a key practical consideration for later-stage development.

While the financing amount and the basic direction of the lead program were disclosed, the report did not provide additional operational details such as how the company plans to structure subsequent clinical steps, what phase the tau-directed degrader is in, or whether any near-term readouts are scheduled. It also did not specify the breakdown of investor participation, including whether any existing backers increased commitments.

The funding highlights ongoing investor interest in “targeted protein degradation” approaches in neurodegeneration. Tau has remained a central focus for drug developers because of its role in neurofibrillary tangles and related disease processes, and because therapies that can meaningfully alter tau biology remain a high bar in the field.

For Lilly, backing Oyster places the company within a broader strategy of developing and investing across drug modalities beyond traditional antibodies and small-molecule inhibitors. Lilly’s financial involvement also underscores how larger pharmaceutical companies are increasingly tied to early-stage platform bets and focused therapeutic programs, especially in areas where standard approaches have struggled.

As with many preclinical or early-development announcements, important details remain unreported in the coverage. The company did not disclose specific financial terms beyond the gross amount raised, nor did it spell out the candidate’s exact clinical status, target patient population, biomarkers, or trial timelines in the reported account.

Investors and patients alike will likely look for further updates on the tau degrader program, including the candidate’s development stage, any planned clinical study designs, and the specific targets within the tau pathway that the degrader is intended to affect. Those details would determine how quickly the program can translate from concept to measurable clinical progress.